INOTREM
Inotrem, an advanced clinical stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes, announced today it received funding from the Crohn’s & Colitis Foundation’s IBD Ventures under a program to accelerate research and development that aim to improve the quality of life for patients with IBD. The funding will support the development of a new therapeutic approach in IBD focusing on the TREM-1 pathway.
The funding follows a R&D collaboration between Inotrem, and the Crohn’s & Colitis Foundation announced in April 2022. The R&D collaboration seeks to pave the way of a personalized medicine approach in IBD patients based on TREM-1. Under the terms of the agreement, Inotrem has access to data and bio-samples from Foundation’s IBD Plexus®, which is the largest IBD database in the US with data from over 25,000 patients. Lasting over 18 months, the project will be a cornerstone in the design of Inotrem’s first-in-human clinical study with INO-02.
There are today 10 million people worldwide suffering from IBD, and the need for new therapeutic options remains very strong. Approximately 30% of patients are unresponsive to existing therapies and even among the initial responders, in up to 10% the drugs lose efficacy over time. For a decade, Inotrem has been elucidating the biology of TREM-1 as a regulator of the immune response in both acute as well as chronic inflammatory diseases. TREM-1 is a potential important contributor to IBD pathophysiology and targeting this pathway may offer a new treatment option for IBD patients with immune dysregulation.
“We are grateful for the support of such a well-respected organization as The Crohn’s & Colitis Foundation. This funding will help us to expand our patented technology platform centered around the TREM-1 pathway and dedicated to developing new therapies for chronic inflammatory syndromes next to our existing modalities for acute diseases,” indicates Sven Zimmermann, CEO of Inotrem.
“Beyond the financial support, this is a strong recognition of Inotrem’s scientific leadership regarding the role of the TREM-1 pathway in inflammatory processes as well as our robust therapeutic approaches targeting that biological target,” says Marc Derive, Chief Scientific Officer and Cofounder of Inotrem.
About Inotrem
Inotrem S.A. is an advanced clinical stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes. The company has developed a new concept of immunomodulation that targets the TREM-1 pathway to control unbalanced inflammatory responses. Through its proprietary technology platform, Inotrem has developed the first-in-class TREM-1 inhibitor, nangibotide, with potential applications in a number of therapeutic indications such as septic shock and myocardial infarction. In parallel, Inotrem has also launched another program to develop a new therapeutic modality targeting chronic inflammatory diseases. The company was founded in 2013 by Dr Jean-Jacques Garaud, a former head of research and early development at the Roche Group, Prof. Sebastien Gibot and Dr Marc Derive. Inotrem is supported by leading European and North American investors. www.inotrem.com
About the Crohn’s & Colitis Foundation
The Crohn's & Colitis Foundation is the leading non-profit organization focused on both research and patient support for inflammatory bowel disease (IBD), with the mission of curing Crohn's disease and ulcerative colitis, and of improving the quality of life of the millions of Americans living with IBD. The Foundation’s work is dramatically accelerating the research process through investment in research initiatives, while also providing extensive educational and support resources for patients and their families, medical professionals, and the public. For more information, visit crohnscolitisfoundation.org, call 888-694-8872, or email info@crohnscolitisfoundation.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230109005241/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SPIE Announces the Best New Products in the Photonics Industry at Its 18th Annual Prism Awards22.1.2026 17:44:00 CET | Press release
The industry-focused awards recognized innovations in areas such as lasers, quantum tech, sensors, optical materials and components, and XR tech On 21 January, SPIE, the international society for optics and photonics, recognized the top-rated new optics and photonics products with the industry-focused Prism Awards. The gala evening, held during SPIE Photonics West, marked the Prism Awards’ 18th year of honoring companies that are bringing transformative products to market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260122875759/en/ Each year, the SPIE Prism Awards reflect the rapidly growing trajectory, exciting latest developments, and rich technical innovations across photonics and photonics-enabled industries. Each year, the SPIE Prism Awards reflect the rapidly growing trajectory, exciting latest developments, and rich technical innovations across photonics and photonics-enabled industries. This year, the annual cere
Fabasoft Positioned as a Challenger in the 2026 Gartner® Magic Quadrant™ for Quality Management System Software22.1.2026 17:15:00 CET | Press release
Analyst firm publishes overview of providers of quality management software Fabasoft, a leading European cloud vendor for document and business process management, has been positioned as a Challenger with its Fabasoft Approve product by Gartner® in its first Magic Quadrant™ 2026 for Quality Management System Software. In the report, the analyst firm recognizes the company’s strengths and cautions. “Gartner defines the market for quality management system (QMS/eQMS) software as stand-alone digital solutions with embedded emerging technological capabilities that enable organizations to systematically manage, monitor and improve the quality of their products, processes and services.” In its independent report, the IT analyst firm evaluated 12 different vendors based on 15 weighted criteria. “We are delighted that Gartner has positioned our QMS as a Challenger. We see this as confirmation of our strategic direction and our technological innovations, particularly in the field of AI. At the
ClickHouse Announces Native Postgres Service, Offering a Unified Data Stack for Real-Time and AI-Driven Applications22.1.2026 17:00:00 CET | Press release
ClickHouse, Inc., the company behind the world’s fastest real-time analytical database, announced a high-performance, enterprise-grade Postgres service natively integrated with ClickHouse, delivering a unified data stack for developers building modern, real-time and AI-driven applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260122173204/en/ ClickHouse Co-Founders (left to right): Yury Izrailevsky, Aaron Katz, Alexey Milovidov The service is built in partnership with Ubicloud, Inc., an open-source cloud company delivering high-performance Postgres, led by a team with proven track record at Citus Data, Heroku, and Microsoft. This launch reinforces ClickHouse’s commitment to unifying transactional and analytical workloads on a single, scalable foundation. This announcement also builds on ClickHouse’s acquisition of PeerDB Inc. in 2024, a Postgres company whose technology is helping power real-time data synchronizati
World Governments Summit 2026 to Include Largest International Participation Yet22.1.2026 16:59:00 CET | Press release
WGS 2026 Hosts High Level Investment Forum Latin America & Caribbean, and World Laureates Summit's Global First The 2026 edition of the World Governments Summit (WGS) will host the largest ever international participation since its inception and convene several landmark forums, underlining its rising global stature and significance. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260122197654/en/ The 2026 edition of the World Governments Summit is set to welcome the largest-ever international participation in the Summit's history, including 35+ heads of state and 150+ governments, as well as landmark forums, such as the World Laureates Summit, that are marking their global debut (Photo: AETOSWire) The roster of world-leading corporations and knowledge institutions at the global forum includes the International Monetary Fund (IMF), International Finance Corporation (IFC), a member of The World Bank, as well as more than 35 hea
Tageos and Wiliot Partner to Accelerate Ambient IoT, Battery-Free BLE Sensing22.1.2026 16:07:00 CET | Press release
Strategic partnership unlocks latest advancements from Tageos’ Innovation Center of Excellence, starting with the battery-free EOS-654 BLE G3 inlay for Wiliot’s Gen3 IoT Pixel sensor and the Wiliot Intelligence Platform Tageos, a global leader in RFID and wireless IoT inlays and tags, today announced a strategic partnership with ambient IoT pioneer Wiliot. The first outcome of this collaboration is the launch of a new passive Bluetooth® Low Energy (BLE) inlay, the EOS-654 BLE G3. In response growing demand for real-time location and condition monitoring across retail and logistics supply chains, this inlay was developed to support large-scale deployment of Wiliot’s Gen3 IoT Pixel sensor and the Wiliot Intelligence Platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260122940104/en/ The new EOS-654 BLE G3 features a dual-band architecture operating at 2.4 GHz and sub-1 GHz. This inlay design enables longer-range energizi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom